Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE OUTCOMES: Ralinepag in PAH
NCT03626688Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Ralinepag + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoint: Time from randomization to the first adjudicated protocol-defined clinical worsening event up to 3 years. Started Jan 2019; status: completed.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03626688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03626688.